---
title: "BUZZ-Astria rises on FDA's orphan drug tag for its genetic disorder treatment"
description: "Shares of drug developer Astria Therapeuticsrise about 3% to $11.45Co receives FDA orphan drug designation for navenibart for treatment of hereditary angiodemaAngiodema causes swelling of arms, face, "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/215642271.md"
published_at: "2024-09-30T15:43:01.000Z"
---

# BUZZ-Astria rises on FDA's orphan drug tag for its genetic disorder treatment

> Shares of drug developer Astria Therapeuticsrise about 3% to $11.45Co receives FDA orphan drug designation for navenibart for treatment of hereditary angiodemaAngiodema causes swelling of arms, face, legs and intestinal tractOrphan drug tag based on early-to-mid-stage trial, in which drug showed reduced monthly swelling attack rates by 90% to 96% when dosed once or twice over 6 monthsCo expects to get additional results from trial in Q4 and progress navenibart into late-stage trial initiating in Q1 2025Including session’s move, stock up ~47.3% YTD

Shares of drug developer Astria Therapeutics (ATXS.O) rise about 3% to $11.45

Co receives FDA orphan drug designation for navenibart for treatment of hereditary angiodema

Angiodema causes swelling of arms, face, legs and intestinal tract

Orphan drug tag based on early-to-mid-stage trial, in which drug showed reduced monthly swelling attack rates by 90% to 96% when dosed once or twice over 6 months

Co expects to get additional results from trial in Q4 and progress navenibart into late-stage trial initiating in Q1 2025

Including session’s move, stock up ~47.3% YTD

### Related Stocks

- [ATXS.US - Astria Therapeutics](https://longbridge.com/en/quote/ATXS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Egetis Therapeutics 已向 FDA 提交了 Emcitate 的新药申请，并预计将在 2026 年 9 月获得监管决定 | Egetis Therapeutics AB 已于 2026 年 1 月 29 日完成了 Emcitate® (tiratricol) 的滚动美国新药申请 (NDA) 提交。FDA 已授予其罕见儿童疾病认定，这使得 Egetis 在潜在获批 | [Link](https://longbridge.com/en/news/274995320.md) |
| Astria Therapeutics 将被 BioCryst Pharmaceuticals 收购 | Astria Therapeutics 即将与 BioCryst Pharmaceuticals 合并，成为其全资子公司。注册声明和代理声明已提交。纽约的两起诉讼指控 Astria 及其董事会存在疏忽和虚假陈述。Astria 计划对这些其认 | [Link](https://longbridge.com/en/news/270660274.md) |
| BioCryst 制药修订董事会任命的披露内容 | BioCryst Pharmaceuticals Inc. 已修订其 8-K 表格，确认与 Astria Therapeutics, Inc. 的合并已完成。作为此次更新的一部分，Dr. Jill C. Milne 被任命为 BioCrys | [Link](https://longbridge.com/en/news/273557568.md) |
| BioCryst 制药完成对 Astria Therapeutics 的收购 | BioCryst Pharmaceuticals 已完成对 Astria Therapeutics 的收购，交易金额约为 7 亿美元。该交易通过手头现金和来自黑石管理的融资设施的 3.966 亿美元资金进行融资，同时向 Astria 的股东 | [Link](https://longbridge.com/en/news/273660677.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.